Minerva’s $200M Financing Fuels Roluperidone’s Final Phase 3 Push in Schizophrenia—Investors and FDA Aligned
Market Chameleon (Tue, 21-Oct 9:51 AM)
Minerva Neurosciences Secures $200 Million Financing to Drive Roluperidone Through Phase 3 Trial for Schizophrenia
Market Chameleon (Tue, 21-Oct 8:24 AM)
